Literature DB >> 30228935

Immunological effects of BRAF+MEK inhibition.

Paolo A Ascierto1, Reinhard Dummer2.   

Abstract

Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is more evident in patients with favorable baseline characteristics, namely normal levels of lactate dehydrogenase, without brain metastases, and low tumor burden. This long-term benefit of targeted therapies might be related to an immune-modulation: indeed BRAF and MEK inhibitors affect tumor microenvironment and immune surveillance, and it has been shown that patients with complete response to targeted treatment have a pre-existing favorable immunologic signature.

Entities:  

Keywords:  BRAF; MEK; advanced melanoma; immune therapy; target therapy

Year:  2018        PMID： 30228935      PMCID： PMC6140547          DOI： 10.1080/2162402X.2018.1468955

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  30 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.

Authors:  Paolo A Ascierto; Georgina V Long
Journal:  Lancet Oncol       Date:  2016-06-17       Impact factor: 41.316

3.  Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

Authors:  Dirk Schadendorf; Jedd D Wolchok; F Stephen Hodi; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; Jason Chesney; Caroline Robert; Kenneth Grossmann; David McDermott; Dana Walker; Rafia Bhore; James Larkin; Michael A Postow
Journal:  J Clin Oncol       Date:  2017-08-25       Impact factor: 44.544

4.  Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Authors:  Reinhard Dummer; Paolo A Ascierto; Helen J Gogas; Ana Arance; Mario Mandala; Gabriella Liszkay; Claus Garbe; Dirk Schadendorf; Ivana Krajsova; Ralf Gutzmer; Vanna Chiarion-Sileni; Caroline Dutriaux; Jan Willem B de Groot; Naoya Yamazaki; Carmen Loquai; Laure A Moutouh-de Parseval; Michael D Pickard; Victor Sandor; Caroline Robert; Keith T Flaherty
Journal:  Lancet Oncol       Date:  2018-03-21       Impact factor: 41.316

5.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

6.  Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Authors:  Julia Boshuizen; Louise A Koopman; Oscar Krijgsman; Aida Shahrabi; Elke Gresnigt- van den Heuvel; Maarten A Ligtenberg; David W Vredevoogd; Kristel Kemper; Thomas Kuilman; Ji-Ying Song; Nora Pencheva; Jens Thing Mortensen; Marnix Geukes Foppen; Elisa A Rozeman; Christian U Blank; Maarten L Janmaat; David Satijn; Esther C W Breij; Daniel S Peeper; Paul W H I Parren
Journal:  Nat Med       Date:  2018-01-15       Impact factor: 53.440

7.  Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

Authors:  Paolo A Ascierto; Ester Simeone; Diana Giannarelli; Antonio M Grimaldi; Anna Romano; Nicola Mozzillo
Journal:  J Transl Med       Date:  2012-05-28       Impact factor: 5.531

Review 8.  A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.

Authors:  Joao Paulo da Silveira Nogueira Lima; Mina Georgieva; Benjamin Haaland; Gilberto de Lima Lopes
Journal:  Cancer Med       Date:  2017-05-01       Impact factor: 4.452

9.  Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells.

Authors:  Bastian Schilling; Annette Paschen
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

10.  Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Authors:  Matteo S Carlino; Vito Vanella; Christina Girgis; Diana Giannarelli; Alex Guminski; Lucia Festino; Richard F Kefford; Alexander M Menzies; Georgina V Long; Paolo A Ascierto
Journal:  Br J Cancer       Date:  2016-10-06       Impact factor: 7.640
View more
  24 in total

1.  A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma.

Authors:  Maria Chiara Tronconi; Arianna Marinello; Alessandra Solferino; Susanna Grimaudo; Michele Ciccarelli; Sofia Manara; Luca Cozzaglio; Luca Mancini; Riccardo Borroni; Armando Santoro
Journal:  Case Rep Oncol       Date:  2022-05-30

Review 2.  Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer.

Authors:  Carolina Mendonça Gorgulho; Anuradha Krishnamurthy; Anastasia Lanzi; Jérôme Galon; Franck Housseau; Ramon Kaneno; Michael T Lotze
Journal:  J Immunother       Date:  2021 Feb-Mar 01       Impact factor: 4.912

Review 3.  Cutaneous Melanoma - A Review of Systemic Therapies.

Authors:  Karla A Lee; Paul Nathan
Journal:  Acta Derm Venereol       Date:  2020-06-03       Impact factor: 3.875

Review 4.  Targeted Therapy in Melanoma and Mechanisms of Resistance.

Authors:  Anna M Czarnecka; Ewa Bartnik; Michał Fiedorowicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2020-06-27       Impact factor: 5.923

Review 5.  New paradigm for stage III melanoma: from surgery to adjuvant treatment.

Authors:  Paolo Antonio Ascierto; Lorenzo Borgognoni; Gerardo Botti; Michele Guida; Paolo Marchetti; Simone Mocellin; Paolo Muto; Giuseppe Palmieri; Roberto Patuzzo; Pietro Quaglino; Ignazio Stanganelli; Corrado Caracò
Journal:  J Transl Med       Date:  2019-08-14       Impact factor: 5.531

Review 6.  Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review.

Authors:  Qingliang Yu; Jiayi Xie; Jiangmiao Li; Yunxin Lu; Liang Liao
Journal:  Cancer Med       Date:  2019-08-08       Impact factor: 4.452

7.  Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.

Authors:  Francesca Consoli; Ausilia Maria Manganoni; Salvatore Grisanti; Fausto Petrelli; Marina Venturini; Giovanni Rangoni; Francesco Guarneri; Paolo Incardona; William Vermi; Pier Giacomo Calzavara Pinton; Alfredo Berruti
Journal:  PLoS One       Date:  2019-04-02       Impact factor: 3.240

8.  Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.

Authors:  Reinhard Dummer; Celeste Lebbé; Victoria Atkinson; Mario Mandalà; Paul D Nathan; Ana Arance; Erika Richtig; Naoya Yamazaki; Caroline Robert; Dirk Schadendorf; Hussein A Tawbi; Paolo A Ascierto; Antoni Ribas; Keith T Flaherty; Neha Pakhle; Catarina D Campbell; Daniel Gusenleitner; Aisha Masood; Jan C Brase; Eduard Gasal; Georgina V Long
Journal:  Nat Med       Date:  2020-10-05       Impact factor: 53.440

9.  Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.

Authors:  Henner Stege; Maximilian Haist; Michael Schultheis; Maria Isabel Fleischer; Peter Mohr; Friedegund Meier; Dirk Schadendorf; Selma Ugurel; Elisabeth Livingstone; Lisa Zimmer; Rudolf Herbst; Claudia Pföhler; Katharina Kähler; Michael Weichenthal; Patrick Terheyden; Dorothée Nashan; Dirk Debus; Martin Kaatz; Fabian Ziller; Sebastian Haferkamp; Andrea Forschner; Ulrike Leiter; Alexander Kreuter; Jens Ulrich; Johannes Kleemann; Fabienne Bradfisch; Stephan Grabbe; Carmen Loquai
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

Review 10.  Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.

Authors:  Magdalena Olbryt; Marcin Rajczykowski; Wiesława Widłak
Journal:  Int J Mol Sci       Date:  2020-06-06       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.